Dermacell is a decellularized regenerative human tissue matrix allograft processed using proprietary MATRACELL® technology from LifeNet Health.
LifeNet Health has over 30 years of experience in tissue processing and holds the longest-running accreditation with the American Association of Tissue Banks (AATB).1
Sterility assurance level (SAL) 10-6 and ready to use - no rinsing required.
Dermacell is decellularized using Matracell, a proprietary and patented technology that removes at least 97% of donor DNA without compromising the desired biomechanical structure or biochemical properties for its intended use.2
After being rendered acellular, Dermacell undergoes a terminal sterilization step to ensure a Sterility Assurance Level (SAL) of 10-6.
Low-dose gamma irradiation performed at ultra-low temperatures is used to reach surgical device-grade sterility, which lowers the probability of an active organism in the graft to 1 in 1,000,000.2
Sterility assurance level (SAL) 10-6.2
Ready to use (RTU)
No rinsing required.2
≥97% Donor DNA-Free
A proprietary and patented technology that removes at least 97% of donor DNA without compromising the desired biomechanical structure or biochemical properties for its intended use.2
Dermacell provides a medical device-grade sterility assurance level of 10-6 and requires no rinsing prior to application.2 The graft features a wide suture border to further support intraoperative placement.
1. For more information, go page: https://www.lifenethealth.org/about/lifenet-health-advantage"
2. Data on file. CTO #100038 63.00050.01 Rev.10 Dermacell IFU
Dermacell, Matracell and Preservon are registered trademarks of LifeNet Health, Inc.
Lit number: 1000902763 Rev A